Imatinib for Pulmonary Arterial Hypertension - Wonder Drug or Killer Drug?

Publisher： Karger

E-ISSN： 1423-0356|89|6|513-514

ISSN： 0025-7931

Source： Respiration, Vol.89, Iss.6, 2015-06, pp. : 513-514

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment

By  

Respiration, Vol. 94, Iss. 1, 2017-05 ,pp. : 26-37

Karger

Access to resources Recommend Favorite

Pulmonary Arterial Hypertension-Specific Drug Therapy in COPD Patients with Severe Pulmonary Hypertension and Mild-to-Moderate Airflow Limitation

By  

Respiration, Vol. 91, Iss. 1, 2016-0 ,pp. : 9-17

Karger

Access to resources Recommend Favorite

Efficacy and Safety of Long-Term Imatinib Therapy for Pulmonary Arterial Hypertension

By  

Respiration, Vol. 89, Iss. 6, 2015-06 ,pp. : 515-524

Karger

Access to resources Recommend Favorite

Riociguat: A Novel New Drug for Treatment of Pulmonary Hypertension

By  

PHARMACOTHERAPY: THE JOURNAL OF HUMAN PHARMACOLOGY AND DRUG THERAPY, Vol. 35, Iss. 5, 2015-05 ,pp. : 502-519

John Wiley & Sons Inc

Access to resources Recommend Favorite

Drug-Induced Pneumonitis Associated with Imatinib Mesylate in a Patient with Idiopathic Pulmonary Fibrosis

By  

Respiration, Vol. 75, Iss. 3, 2006-01 ,pp. : 350-354

Karger

Access to resources Recommend Favorite